Site içinde arama yapın

bir ses eklendi Health

2026-06-04 11:18:21 -

Antibody Radionuclide Conjugates Market: How Is Lutetium-177 PSMA Therapy Creating the Prostate Cancer Theranostic Revolution?

Lu-177 PSMA radioligand therapy — the Pluvicto (Novartis) and similar PSMA-targeting antibody/small molecule conjugates with beta-emitting Lu-177 achieving metastatic castration-resistant prostate cancer (mCRPC) survival benefit representing the most clinically advanced radiopharmaceutical — creates the most commercially dynamic market segment, with the Antibody Radionuclide...

0 Yorumlar 0 hisse senetleri 94 Views 0 önizleme